Wiśniewski

SoniVie Raises $60m in Round C Financing, and Appoints New Board Members

Retrieved on: 
Monday, January 9, 2023
The Company, TEL, Stroke, Kidney failure, Medtech, Risk, Patient, Hypertension, Renal artery, Axon Sports, Physician, Therapy, Blood pressure, Pharmaceutical industry, Wiśniewski

TEL AVIV, Israel, Jan. 9, 2023 /PRNewswire/ -- SoniVie Ltd. ("SoniVie" or the "Company"), a medical device company developing a proprietary solution to treat hypertension, announced today the completion of a $60 million series C round financing. The financing was led by Andera Partners, with participation from Supernova Invest and Omega Funds. Current SoniVie shareholder TechWald also participated.

Key Points: 
  • In conjunction with the financing, the Company appointed two renowned medtech experts to its Board of Directors, Raymond W. Cohen and Zeev Zehavi, as independent directors.
  • The proceeds from SoniVie financing are envisioned to be used to reach clinical and regulatory milestones and to support TIVUS™ renal artery denervation program.
  • Raphaël Wisniewski of Andera Partners commented, "SoniVie TIVUS™ has the potential to provide patients and physicians with a safe, efficient and easy to use device.
  • We are thrilled to support this talented management together with our syndicate partners and our new board members".

SoniVie Raises $60m in Round C Financing, and Appoints New Board Members

Retrieved on: 
Monday, January 9, 2023
The Company, TEL, Stroke, Kidney failure, Medtech, Risk, Patient, Hypertension, Renal artery, Axon Sports, Physician, Therapy, Blood pressure, Pharmaceutical industry, Wiśniewski

TEL AVIV, Israel, Jan. 9, 2023 /PRNewswire/ -- SoniVie Ltd. ("SoniVie" or the "Company"), a medical device company developing a proprietary solution to treat hypertension, announced today the completion of a $60 million series C round financing. The financing was led by Andera Partners, with participation from Supernova Invest and Omega Funds. Current SoniVie shareholder TechWald also participated.

Key Points: 
  • In conjunction with the financing, the Company appointed two renowned medtech experts to its Board of Directors, Raymond W. Cohen and Zeev Zehavi, as independent directors.
  • The proceeds from SoniVie financing are envisioned to be used to reach clinical and regulatory milestones and to support TIVUS™ renal artery denervation program.
  • Raphaël Wisniewski of Andera Partners commented, "SoniVie TIVUS™ has the potential to provide patients and physicians with a safe, efficient and easy to use device.
  • We are thrilled to support this talented management together with our syndicate partners and our new board members".

EQS-News: Andera Partners invests in SoniVie, a medtech company developing a promising device for the treatment of hypertension

Retrieved on: 
Sunday, January 22, 2023
The Company, TEL, Stroke, Kidney failure, Medtech, Risk, Partner, Patient, Hypertension, Renal artery, Physician, Therapy, Blood pressure, Pharmaceutical industry, Wiśniewski, Axon Sports

TEL AVIV, ISRAEL, AND PARIS, FRANCE, JANUARY 10, 2023 -- SoniVie Ltd. ("SoniVie" or the "Company"), a medical device company developing a proprietary solution to treat hypertension, announced today the completion of a $60 million series C round financing. The financing was led by Andera Partners, with participation from Supernova Invest and Omega Funds. Current SoniVie shareholder TechWald also participated.

Key Points: 
  • Andera Partners invests in SoniVie, a medtech company developing a promising device for the treatment of hypertension
    The issuer is solely responsible for the content of this announcement.
  • The financing was led by Andera Partners, with participation from Supernova Invest and Omega Funds.
  • Raphaël Wisniewski of Andera Partners commented, "SoniVie TIVUS™ has the potential to provide patients and physicians with a safe, efficient and easy to use device.
  • We are thrilled to support this talented management together with our syndicate partners and our new board members".